ArticleBritish journal of cancer2022

Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?

Roberto Moretto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.